Skip to main content

Table 3 Treatment modalities and outcomes of women with neuroendocrine carcinoma of the cervix

From: Neuroendocrine carcinoma of the cervix: a systematic review of the literature

Author Year N Treatment modalities (Initial) Treatment modalities (Recurrence) Chemotherapy regimens adjuvant/Neo-Adjuvant Chemotherapy regimens recurrence/primary advanced RXT (n)/Gray Recurrence-free survival duration (m) Overall survival duration (m) 2- or 3-Year Overall survival rate (%) 5-Year overall survival rate (%)
Paraghamian [149] 2017 1 S + CHXT CHXT, RXT, NIV EP PACTOP 1 7
Wu [128] 2017 1 NACT+S + CHXT IfoEP 78 78
Xie [158] 2017 48 NACT+S + CHXT, S + RXT, S + CHXT EP, CPAC, BEP 30 57 31
Lee [142] 2016 61 S + CHXT, RXCT, S + RXCT, CHXT EP, CPAC, FUP 64 36
Rajkumar [151] 2016 1 S + CHXT EP 18 18
Robin [100] 2016 100 RCXT, NACT+RCXT 48   
Stecklein [153] 2016 40 S, S + RXT, RXT + CHXT, RCXT 9 30 27
Nagao [86] 2015 23 S + CHXT, S + RCXT, RXT CPAC, IP 64
Singh [105] 2015 1 S + CHXT EP 26 26
Wang [156] 2015 1 NACT+RXCT EP, N −/25 6 6
Yin [12] 2015 23 NACT+S + CHXT, NACT+S + RXT + CHXT EP 69 (3), 54 (20) 55 39
Dongol [139] 2014 4 NACT+S + CHXT EP, VPB 10
Lyons [144] 2014 1 NACT+S + RXCT MEK-Inh EP TRAM 1/45 4 12
Omori [148] 2014 1 NACT+S + CHXT IP 21 21
Kim [63] 2013 1 S + RCXT CHXT, S CPAC, EP 1/50 4 12
McCann [146] 2013 26 S, NACT+S, S + RXT CHXT EP EPA 34 49 71
Murakami [147] 2013 1 CHXT IP 3 5
Lin [78] 2012 5 RXT, RXCT, S + RXCT CHXT FUP, EPD 6 22
Peng [150] 2012 14 S + RXT + CHXT, S + CHXT EP, FUP, EP + CPAC 6 32 40 25
Teefey [114] 2012 1 NACT+S EP 24 24
Komiyama [66] 2011 1 S + CHXT CHXT, RXT EPPAC IP 11 19
Nasu [13] 2011 1 NACT+S + CHXT CHXT IP AMR, EP 0 27
Bifulco [27] 2009 1 S + RXT + CHXT CPAC 12 12
Li [77] 2009 1 RXCT EP 1/63 21 21
Wang [123] 2009 7 S, S + CHXT, S + RXT EP, EPEpi, P, PE 32 28
Zivanovic [159] 2009 17 S + CHXT, RXCT EP −/14 21 30
Lee [71] 2008 68 S, NACT+S + RXCT, NACT+S + RXT EP, CPAC, VPB, IPPAC 54 64.6 46.6
Kasamatsu [62] 2007 10 S, S + RXT, S + CHXT EP, PDC 2/45–50 8 29 43
Ko [64] 2007 1 S + RCXT+CHXT P 1/53 24 24
Tangjitgamol [113] 2007 1 S + CHXT CHXT CPAC CPAC, EP 19 27
Baykal [26] 2005 1 S + CHXT+RCXT EP 1/50 21 21
Tangjitgamol [112] 2005 24 S, S + CHXT, S + RXT, RCXT, RXT, CHXT 21
Tsunoda [117] 2005 11 S + CHXT, S + RXT, RCXT EP, PPep 3/50; 2/80 27 27
Trinh [116] 2004 1 S + CHXT+RCXT 52 52
Viswanathan [121] 2004 21 S, RXT, RCXT, S + CHXT, NACT+RXT EP, EPD 41 29
Hoskins [14] 2003 34 CHXT+RCXT EP, CPAC 60
Sato [101] 2003 6 S + RXT + CHXT 36 33
Bermúdez [15] 2001 20 S + RXT, NACT+S, CHXT VBP −/50 39 60 39
Boruta [137] 2001 11 S + CHXT VAC, EP 24 38
Collinet [38] 2000 5 S + CHXT, S + RXT, RXT   EP, EDC 3/55–105 15 17
Delaloge [42] 2000 3 S + RXT, S + CHXT, S + RXCT PVep 16 33 20
McGarry [85] 1999 1 NACT+RXT S EP −/83 0 18
Abulafia [19] 1995 3 S + CHXT, S + CHXT+RXT RXT EVP-16 30 36
Lewandowski [143] 1993 4 S + CHXT, CHXT+RXT, NACT+S + RXT, NACT+CHXT EPD 2/45 25
Gersell [49] 1988 15 S, RXT, S + RXT, RXT + CHXT * 18 33
Sheets [103] 1988 14 S, S + RXT 8/45–60 19 15
Walker [122] 1988 14 RXT, S, CHXT, S + CHXT, RXT + CHXT VDaCy 14 14
Turner [118] 1986 1 S + CHXT+RXT VACyMVP 1/45 2 4
Pooled Analysis    S + CHXT (21/48); NACT+S ± Other (12/48); RXT/RCXT or RXT + CHXT (15/43) CHXT (7/10); RXT (3/10); S (2/10) EP (24/40); EP + Other (6/40); CPAC (7/40); IP (4/40); FUP (3/40) EP ± Other (5/8) 16 Months 40 Months 50% 34%
  1. Abbreviations: NACT Neoadjuvant Chemotherapy, S Surgery, RCXT Radio-Chemotherapy, E Etoposide, P Cisplatin/Carboplatin, CHXT Chemotherapy, I Irinotecan, AMR Amrubicin, PAC Paclitaxel, Ifo Ifosfamide, ICI Immune-Checkpoint-Inhibitor, FU 5-Fluorouracil, Epi Epirubicin, D Doxorubicin, C Cyclophosphamide, Pep Peplomycin, Vep Vepesid, * Various combinations including Cisplatin, Cytoxan, Methotrexate, Procarbazin, and VP-16¸ VDaCy, Vincristin, Daunorubicin, Cytoxan, VACMVP Vincristin, Adriamycin, Cyclophosphamide, Methotrexate, VP-16, V Vincristine/Vinblastin, TOP Topotecan, NIV Nivolumab, N Nedaplatin, MEKInh MEK-Inhibitor, TRAM Trametinib, A Adriamycin